ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a randomized, double-blinded, placebo controlled Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma in multiple centers in the United States. For further information, visit the Company’s Web site at www.imuc.com.

Noble Financial, a research driven, full-service investment banking boutique, is as discriminating with its invitations to institutional investors as it is with the companies invited to present. Rather than just focusing on crowding the conference floor, Noble Financial carefully invites a smaller audience of investors with a large appetite for the companies presenting; quality always trumps quantity. For more information or to view webcasts of today’s presentations, visit www.noblefcm.com.

Let us hear your thoughts below: